Searching for a Covid Treatment
For high-risk seniors changing how they connect is a must during Coronavirus, and searching for a treatment.
Scynexis’ new antifungal on track for 2020 filing with phase 3 win
After outshining the standard of care for yeast infections in a midstage trial, Scynexis’ broad-spectrum antifungal has delivered again. The drug beat placebo at clearing up vulvovaginal candidiasis in a second phase 3 study, teeing up an FDA submission in the second half of 2020.
Breakthrough in neurodegeneration: GV, Bill Gates and Foresight invest $45m in Cerevance
GV, Bill Gates and Foresight Capital joined three existing investors in Cerevance’s recent Series B round, which closed with $45m raised. The ability of this brain disease-focused drug discovery company to close a lucrative round with such high-profile investors amid the Covid-19 pandemic is impressive, but how will the new financing impact the Cerevance’s future?
“Who Are They?” A Biotech CEO’s Timeless Question For CDMOs
The question James E. Brown, President & CEO, DURECT asked of CDMOs when he founded the company in 1998 remains perfectly operational. “‘Who are they?’ is the most important question for me regarding our external partners,” he tells me from his corporate headquarters in Cupertino, CA.
San Diego biotech company launches trials of drug to treat COVID-19 pneumonia
San Diego biotech company CalciMedica has partnered with two Midwestern hospitals to test a drug designed to help COVID-19 patients who are battling severe pneumonia.
Cerevance Banks $45 Million for Neurological Drug Development
Biotechnology startup Cerevance Inc. has secured $45 million to hunt for treatments for neurological diseases by studying samples of brain tissue gathered from deceased donors world-wide.
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying the right antibodies from recovered COVID-19 patients and hoping to use them as a template for synthesizing new ones, in a more consistent and efficient way so a handful of donors could potentially produce enough antibodies to treat millions of patients. “What GigaGen’s technology does is almost Xerox copy a big swath of the human repertoire of antibodies, and then takes those copies and grows it in cells [in the lab] to manufacture more antibodies outside of the human body,” says Meyer.
